| 期 |
栏目 |
标题 |
文件 |
| 卷 21, 编号 3 (2019) |
Articles |
Effect of starting dose of regorafenib on overall survival of patients with metastatic colorectal cancer: a systematic review and meta-analysis |
|
| 卷 23, 编号 1 (2021) |
CLINICAL ONCOLOGY |
Comparison of the efficacy of first-line therapy with different generations of EGFR tyrosine kinase inhibitors in patients with advanced EGFR-associated non-small cell lung cancer: a network meta-analysis of overall survival data |
(Rus)
|
| 卷 23, 编号 4 (2021) |
CLINICAL ONCOLOGY |
Multicenter prospective observational post-approval study of safety and efficacy of bevacizumab (Avegra®, BIOCAD) in patients with metastatic colorectal cancer in real world practice: APOLLON-11 and SOYUZ-APOLLON |
(Rus)
|
| 卷 25, 编号 1 (2023) |
CLINICAL ONCOLOGY |
The possibilities of therapy of patients with metastatic colorectal cancer with BRAF V600E mutation. Clinical cases |
(Rus)
|
| 卷 24, 编号 4 (2022) |
CLINICAL ONCOLOGY |
Real-world efficacy of the first line therapy with prolgolimab in patients with metastatic melanoma: interim results of the FORA (FOrteca Real practice Assessment) observational study |
(Rus)
|
| 卷 25, 编号 3 (2023) |
CLINICAL ONCOLOGY |
Resolution of the advisory board on the topic: “The place of entrectinib in the treatment of adult patients with NTRK-fusion positive solid tumors” |
(Rus)
|
| 卷 26, 编号 1 (2024) |
Articles |
Venous thrombosis during systemic antitumor therapy: risks, prognosis, treatment |
(Rus)
|
| 卷 26, 编号 1 (2024) |
Articles |
Final data on the efficacy of the FORA study (FOrteca Real practice Assessment): a multicenter prospective observational study on the real-world efficacy of prolgolimab in patients with metastatic melanoma in Russia |
(Rus)
|
